Melphalan
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Melphalan: From Chemotherapy Backbone to Gonadal Germ Cell Tumor
One-Sentence Summary
Melphalan (DrugBank DB01042) is a classic cytotoxic alkylating chemotherapy agent; this evidence pack does not include a Taiwan-approved original indication text since the drug is not currently marketed in Taiwan. The TxGNN model predicts it may be effective for Gonadal Germ Cell Tumor, with 8 clinical trials and 4 publications currently supporting this direction, largely reflecting melphalan’s established role in high-dose chemotherapy/autologous stem cell transplant (ASCT) salvage regimens for relapsed germ cell tumors.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in this evidence pack (drug currently unmarketed in Taiwan; internationally melphalan is classically indicated for multiple myeloma and ovarian carcinoma — general background, not sourced from this pack) |
| Predicted New Indication | Gonadal Germ Cell Tumor |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L2 |
| US Market Status | ✗ Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Drug-level mechanism-of-action data is flagged as a data gap (DG002) in this pack. However, disease-specific rationale notes within the evidence do describe melphalan as a bifunctional alkylating agent (a phenylalanine-derived nitrogen mustard) that induces DNA cross-linking and apoptosis in rapidly dividing cells — consistent with its well-documented use as a conventional cytotoxic chemotherapy agent.
Testicular/gonadal germ cell tumors are known to be highly sensitive to alkylating agents. High-dose melphalan combined with autologous stem cell transplant rescue is already an established oncology salvage strategy for relapsed or refractory germ cell tumors, rather than a wholly novel hypothesis — this is reflected directly in the trial evidence below (e.g., NCT00936936, a disease-specific Phase 2 study). The TxGNN prediction therefore aligns with existing, though not disease-label-approved, clinical practice patterns.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00936936 | Phase 2 | Completed | 64 | High-dose chemotherapy (gemcitabine/docetaxel/melphalan/carboplatin, then ifosfamide/carboplatin/etoposide) for poor-prognosis relapsed germ-cell tumors — disease-specific (Grade A relevance) |
| NCT00003425 | Phase 1/2 | Completed | 25 | Escalating-dose melphalan with autologous stem cell support and amifostine cytoprotection in cancer patients (not disease-specific) |
| NCT00638898 | Phase 1 | Completed | 25 | Busulfan + melphalan + topotecan followed by ASCT in advanced/recurrent solid tumors |
| NCT00060255 | Phase 2 | Completed | 451 | Autologous blood/marrow transplantation across hematologic malignancies and selected solid tumors (broad population) |
| NCT00003926 | Phase 1 | Terminated | 13 | Amifostine chemoprotection with ASCT for high-risk/relapsed pediatric solid and brain tumors |
| NCT00536601 | N/A | Completed | 174 | High-dose regimens ± total-body irradiation before ASCT for hematologic cancers and selected solid tumors |
| NCT01272817 | N/A | Completed | 36 | Nonmyeloablative allogeneic HSCT (ATG + melphalan/cladribine or TLI) across various hematologic illnesses |
| NCT00002750 | Phase 1 | Completed | 6 | Intrathecal melphalan for recurrent neoplastic meningitis (different indication/route; low relevance) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 4270380 | 1973 | Review | Oncology | Chemotherapy of testicular germinal tumors (abstract not available in pack; title-level relevance) |
| 24913 | 1977 | Review | Urologic Clinics of North America | Seminoma treatment review (abstract not available in pack) |
| 13392619 | 1956 | Cohort | Voprosy onkologii | Historical experience treating testicular seminoma and its metastases with sarcolysin (an early name for melphalan) |
| 14151951 | 1964 | Other (endocrine mechanism) | Acta Unio Internationalis Contra Cancrum | Influence of hormonal and alkylating drugs on pituitary FSH-stimulating function — mechanistic, not a direct treatment study |
Note: abstracts were not populated in this evidence pack for these older publications; summaries above are based on titles only.
Cytotoxicity
Melphalan is a conventional cytotoxic alkylating chemotherapy agent, and all current predicted indications are oncologic — this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating agent, nitrogen mustard/phenylalanine derivative) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions (no drug-specific toxicity data in this evidence pack) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information. This evidence pack flags TFDA label warnings/contraindications as a Blocking data gap (DG001) — safety data was not available and formal S1 safety pre-assessment could not be completed.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: One disease-specific completed Phase 2 trial (NCT00936936) plus established oncologic practice (melphalan-containing high-dose ASCT salvage regimens for relapsed germ cell tumors) support L2-level evidence. However, the drug is not currently marketed in Taiwan and TFDA label/safety data is a blocking gap, so this cannot yet advance without guardrails.
To proceed, the following is needed:
- TFDA-equivalent label warnings/contraindications (DG001, blocking) before any S1 safety pre-assessment
- Confirmed mechanism-of-action documentation (DG002)
- Taiwan market/registration pathway assessment, since total_licenses = 0
- Route-of-administration compatibility confirmation (currently pending in the pack)
Note: Lower-ranked candidates (ovarian primitive germ cell tumor, L3; choriocarcinoma of ovary and the five mucinous adenocarcinoma indications, all L5/Hold) lack clinical or literature support and are flagged in the pack as likely reflecting TxGNN embedding-cluster similarity rather than independent signal — not recommended for near-term investment.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.